Skip to main content
Linvoseltamab for Relapsed/Refractory Multiple Myeloma: Updates on the LINKER-MM1 Trial From AACR 2024 With Alankrita Taneja, MD, and Sundar Jagannath, MD
Keira Smith
Expert Analysis
In this interview from the American Association for Cancer Research (AACR) 2024 Annual Meeting, Dr. Alankrita Taneja, third-year Hematology/Oncology Fellow at Roswell Park Cancer Institute and Oncology Data Fellows Forum Member, speaks with Dr. Sundar Jagannath, Professor of Medicine (Hematology and Medical Oncology) and Director of the Center of E...
Multiple Myeloma Awareness Month 2024: What Patients Need to Know
Keira Smith
Expert Analysis
Oncology Data Advisor® · Multiple Myeloma Awareness Month 2024: What Patients Need to Know For Multiple Myeloma Awareness Month this March, Oncology Data Advisor hosted a live panel discussion geared towards patients living with multiple myeloma. Dr. Rahul Banerjee, Dr. Alankrita Taneja, Dr. Richa Thakur, and Dr. Gurbakhash Kaur helped p...
Racial and Socioeconomic Disparities in the CLL Community Oncology Setting With Ira Zackon, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Racial and Socioeconomic Disparities in the CLL Community Oncology Setting: Ira Zackon, MD At the recent 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Ira Zackon, MD, a Senior Medical Director with Ontada, to discuss his abstract and presentation about racial a...
Guiding Dietary Choices During Multiple Myeloma Treatment With Richa Parikh, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Guiding Dietary Choices During Multiple Myeloma Treatment: Richa Parikh, MD In this interview from the 2023 American Society of Hematology Annual Meeting, Richa Parikh, MD, a third-year Hematology/Oncology Fellow at Karmanos Cancer Institute, discusses her team's study investigating the role of diet in multiple myeloma and how its findings can be used to help guide dietary decisions for patients.  
Highlights of Multiple Myeloma Research Presented at ASH With Urvi Shah, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Highlights of Multiple Myeloma Research Presented at ASH 2023: Urvi Shah, MD At the recent American Society of Hematology (ASH) Annual Meeting, numerous updates were presented with the potential to impact practice in relapsed/refractory multiple myeloma. While at the meeting, Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, shares some of most significant highlights of the clinical trials and therapeutic agents being presented. After listening to the podcast, be sure to watch Dr. Shah's free CME activity or book a live meeting for your institution to hear more expert perspectives on new directions in multiple myeloma treatment!  
Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma With Swetha Kambhampati, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma: Swetha Kambhampati, MD At the recent American Society of Hematology (ASH) Annual Meeting, Swetha Kambhampati, an Assistant Professor in the Division of Lymphoma at City of Hope, sat down with Oncology Data Advisor to further discuss her pr...
Managing Acute Leukemias and Lymphomas When Patients Stay Local With Dipti Patel-Donnelly, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Managing Acute Leukemias and Lymphomas When Patients Stay Local: Dipti Patel-Donnelly, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Dipti Patel-Donnelly, a Medical Oncology at Virginia Cancer Specialists, hosted a session highlighting how to optimize management when patients with hema...
Improving Quality of Life in Multiple Myeloma Through Bortezomib Dose Reduction With Rahul Banerjee, MD, FACP, and Gurbakhash Kaur, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Improving QOL in Multiple Myeloma With Bortezomib Dose Reduction: Rahul Banerjee and Gurbakhash Kaur At the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Rahul Banerjee, Editor in Chief of Oncology Data Advisor, sat down with Dr. Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas (UT) Southwestern Medical Center, to discuss their abstract about real-world dosing and prescribing patterns of bortezomib in newly diagnosed multiple myeloma. Dr. Banerjee and Dr. Kaur debate the pros and cons of once- versus twice-weekly dosing of bortezomib, its impact on tolerability and outcomes, and changes in trial design that are needed to make once-weekly dosing a new standard in clinical practice.  
Real-World Outcomes of Brexucabtagene Autoleucel for B-Cell ALL With Evandro Bezerra, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Real-World Outcomes of Brexuctabtagene Autoleucel for B-Cell ALL: Evandro Bezerra, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Dr. Evandro Bezerra, a Hematology Specialist at the Ohio State University Comprehensive Cancer Center, sat down with Oncology Data Advisor to discuss his team...
Investigating Therapies Targeting Cardiovascular Health in MDS With Diego Adrianzen Herrera, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Investigating Therapies Targeting Cardiovascular Health in MDS: Diego Adrianzen Herrera, MD In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Diego Adrianzen Herrera, a Malignant Hematologist at the University of Vermont Medical Center, about his study investigating the impact of hypomethylating agents on cardiovascular disease risk for patients with myelodysplastic syndromes (MDS). Dr. Adrianzen Herrera explains the study's results and how they can be used to design future research around treatments targeting cardiovascular health in MDS.  
Improving Diversity in Multiple Myeloma Clinical Trials With Craig Cole, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Improving Diversity in Multiple Myeloma Clinical Trials: Craig Cole, MD At the recent American Society of Hematology (ASH) Annual Meeting, Craig Cole, MD, Assistant Professor at Karmanos Cancer Institute, sat down with Oncology Data Advisor to share his passion for improving diversity in multiple myeloma clinical trials. He discusses the efforts that are currently underway to increase diverse accrual and the importance of raising awareness in order to address this issue both within the community and on a global scale.  
Empowering Patients Through Shared Decision Making in Myelodysplastic Syndromes With Claire Saxton, MBA
Keira Smith
Expert Analysis
Oncology Data Advisor® · Empowering Patients Through Shared Decision Making in Myelodysplastic Syndromes: Claire Saxton At the 2023 American Society of Hematology (ASH) Annual Meeting, Claire Saxton, Executive Vice President of Insights and Impact at Cancer Support Community, presented her team's study on communication that enables shared decision making in myelodysplastic syndromes (MDS). While there, she sat down with Oncology Data Advisor to discuss more about the results of the study and ways that health care professionals and patient advocacy groups can partner to ensure that clear and consistent messages are being delivered to patients with MDS so that they can be more informed and involved in their care.  
Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD   At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Brittany Ragon, Adult Leukemia and Transplant Specialist at Levine Cancer Institute, sat down with Oncology Data Advisor to discuss her pr...
CLL Society: Paving the Way for CLL Patients and Survivors With Brian Koffman, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · CLL Society: Paving the Way For CLL Patients and Survivors With Brian Koffman, MD CLL Society is a patient-centric, physician-curated nonprofit organization that prioritizes patient education, advocacy, and research for the chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) community. Dr. Brian Koffman co-founded the organization after being diagnosed with CLL in 2005, and he currently serves as Executive Vice President and Chief Medical Officer. He recently attended the American Society of Hematology (ASH) Annual Meeting to acquire the latest CLL research to bring back and disseminate to patients, and while there, he sat down with Oncology Data Advisor to share more about the educational and advocacy work that the society does, updates in CLL research being presented at the meeting, and how patients with CLL can become more involved and empowered in their treatment and care.  
Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting With David Andorsky, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting: David Andorsky, MD At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Dr. David Andorsky, MD, a Clinical Hematologist and Medical Oncologist at the Rocky Mountain Cancer Centers in Boulder, Colorado, presented ...
A Mobile App to Address Sexual Dysfunction in HSCT Survivors: Areej El-Jawahri, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · A Mobile App to Address Sexual Dysfunction in HSCT Survivors: Areej El-Jawahri, MD After receiving hematopoietic stem cell transplantation (HSCT), many survivors experience issues with sexual dysfunction which can impact their quality of life. To address this challenge, Dr. Areej El-Jawahri, Director of the Bone Marrow Transplant Survivorship Program at Massachusetts General Hospital (MGH), and her team developed a multimodal mobile app as an intervention for sexual health concerns after transplant. After presenting this research at the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. El-Jawahri sat down with Oncology Data Advisor to further explain the app's development and efficacy, as well as additional ways it can be used to improve quality of life for transplant survivors in the future.  
Exploring Results of the IsKia Trial in Newly Diagnosed Multiple Myeloma With Annemiek Broijl, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Exploring Results of the IsKia Trial in Newly Diagnosed Multiple Myeloma: Annemiek Broijl, MD In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Annemiek Broijl, Hematologist at Erasmus MC Cancer Institute in the Netherlands, discusses the IsKia trial, of which she is the Co-Primary Investigator, and its unique primary end point of measurable residual disease (MRD).  
Financial Hardship Experienced During Transplant in Myelodysplastic Syndromes With Christopher Su, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Financial Hardship Experienced During Transplant in Myelodysplastic Syndromes: Christopher Su, MD At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Christopher Su, MD, a Hematologist at the Fred Hutchinson Cancer Center, presented his research regarding financial hardships experience...
Coping With Psychological Distress Prior to Hematopoietic Cell Transplantation With Richard Newcomb, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Coping With Psychological Distress Prior to Hematopoietic Cell Transplantation: Richard Newcomb, MD Patients with hematologic malignancies undergoing hospitalization for hematopoietic cell transplantation experience significant psychological distress, and they cope in different ways. In this interview from the 2023 American Society of Hematology (ASH), Dr. Richard Newcomb, Instructor of Medicine at Harvard Medical School, discusses his presentation on coping mechanisms employed by patients who are preparing for transplantation and ways that health care providers can help support their patients during this time.  
Evaluating Outpatient Teclistamab Administration in Multiple Myeloma With Robert Rifkin, MD, FACP
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Evaluating Outpatient Teclistamab Administration in Multiple Myeloma: Robert Rifkin, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Robert Rifkin, MD, FACP, a Board-Certified Medical Oncologist and Hematologist at the Rocky Mountain Cancer Centers in Denver, Colorado, sat down with Onco...